Identification of anticancer drugs to radiosensitise

PARP inhibitor Radiosensitizer colorectal cancer radiotherapy

Journal

Cancer biology & medicine
ISSN: 2095-3941
Titre abrégé: Cancer Biol Med
Pays: China
ID NLM: 101588850

Informations de publication

Date de publication:
May 2019
Historique:
entrez: 14 9 2019
pubmed: 14 9 2019
medline: 14 9 2019
Statut: ppublish

Résumé

Patients with We screened 298 oncological drugs with and without ionising radiation in colorectal cancer cells isogenic for Most consistently identified hits were drugs targeting cell growth/proliferation or DNA damage repair. The most effective class of drugs that radiosensitised wild-type and mutant cell lines was PARP inhibitors. In clonogenic survival assays, talazoparib produced a radiation enhancement ratio of 1.9 in DLD1 ( Our method for screening large drug libraries for radiosensitisation has identified PARP inhibitors as promising radiosensitisers of colorectal cancer cells with wild-type and mutant

Identifiants

pubmed: 31516745
doi: 10.20892/j.issn.2095-3941.2018.0284
pii: cbm-16-2-234
pmc: PMC6713640
doi:

Types de publication

Journal Article

Langues

eng

Pagination

234-246

Subventions

Organisme : Medical Research Council
ID : MC_PC_12006
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00001/6
Pays : United Kingdom

Références

Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Cancer Res. 2003 Oct 15;63(20):6935-41
pubmed: 14583494
Cell. 2004 Mar 19;116(6):855-67
pubmed: 15035987
Cancer Res. 2005 Jul 15;65(14):6063-9
pubmed: 16024606
Acta Oncol. 2005;44(7):687-93
pubmed: 16227158
Ann Oncol. 2006 Mar;17(3):361-71
pubmed: 16500912
Bioinformatics. 2006 Nov 15;22(22):2825-7
pubmed: 16982708
Clin Cancer Res. 2006 Sep 15;12(18):5557-69
pubmed: 17000693
Oncol Rep. 2006 Nov;16(5):1085-91
pubmed: 17016597
Nat Protoc. 2006;1(5):2315-9
pubmed: 17406473
Mol Cancer Ther. 2007 Jun;6(6):1858-68
pubmed: 17575114
Nat Chem Biol. 2007 Aug;3(8):438-41
pubmed: 17637769
Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):858-65
pubmed: 18410996
Br J Cancer. 2009 Aug 4;101(3):465-72
pubmed: 19603024
Nat Rev Clin Oncol. 2009 Dec;6(12):687-97
pubmed: 19884901
J Clin Oncol. 2010 Jan 20;28(3):466-74
pubmed: 20008640
Cancer Biother Radiopharm. 2009 Dec;24(6):689-99
pubmed: 20025549
Nat Rev Cancer. 2010 Apr;10(4):293-301
pubmed: 20200537
Cancer Res. 2010 Apr 1;70(7):2984-93
pubmed: 20233878
Cancer Res. 2010 Jun 15;70(12):4972-81
pubmed: 20501833
Mol Cancer Ther. 2010 Jun;9(6):1775-87
pubmed: 20530711
Lancet Oncol. 2010 Aug;11(8):753-62
pubmed: 20619739
BMC Med Genomics. 2011 Jan 20;4:9
pubmed: 21251323
Clin Cancer Res. 2011 Aug 1;17(15):5038-47
pubmed: 21690569
Genes Cancer. 2011 Mar;2(3):261-74
pubmed: 21779497
Mol Cancer Ther. 2011 Oct;10(10):1949-58
pubmed: 21825006
J Clin Oncol. 2011 Oct 1;29(28):3753-60
pubmed: 21876084
Cancer Lett. 2011 Dec 22;312(2):209-18
pubmed: 21937165
BMC Cancer. 2012 Jun 19;12:260
pubmed: 22712570
Radiother Oncol. 2013 Jan;106(1):138-46
pubmed: 23321494
Radiother Oncol. 2013 Sep;108(3):429-33
pubmed: 23932191
PLoS One. 2013 Dec 12;8(12):e82982
pubmed: 24349411
Mol Cancer Ther. 2014 Feb;13(2):433-43
pubmed: 24356813
Cancer. 2014 Aug 1;120(15):2316-24
pubmed: 24737664
Cancer Res. 2014 Jun 15;74(12):3238-47
pubmed: 24755471
Radiat Res. 2014 Jul;182(1):50-9
pubmed: 24909911
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Curr Gastroenterol Rep. 2015 Feb;17(2):431
pubmed: 25663616
Mol Cancer Res. 2015 Apr;13(4):713-20
pubmed: 25667133
J Pharmacol Exp Ther. 2015 Jun;353(3):446-57
pubmed: 25758918
Ann Oncol. 2015 Jun;26(6):1238-44
pubmed: 25762352
Radiat Oncol. 2015 Feb 27;10:55
pubmed: 25888875
Radiother Oncol. 2015 Nov;117(2):364-75
pubmed: 26163092
World J Gastroenterol. 2015 Jul 7;21(25):7659-71
pubmed: 26167068
Lancet Oncol. 2015 Aug;16(8):979-89
pubmed: 26189067
Radiother Oncol. 2015 Sep;116(3):486-94
pubmed: 26277432
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
J Gastrointest Oncol. 2015 Dec;6(6):650-9
pubmed: 26697198
Sci Rep. 2016 Feb 12;6:20596
pubmed: 26867983
Clin Cancer Res. 2016 Feb 15;22(4):813-20
pubmed: 26880610
Oncotarget. 2016 Apr 19;7(16):22257-70
pubmed: 26989027
Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):772-81
pubmed: 27020103
Br J Cancer. 2016 Mar 29;114(7):713-5
pubmed: 27022824
Nat Rev Clin Oncol. 2016 Oct;13(10):627-42
pubmed: 27245279
Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1399-1404
pubmed: 27319288
Mol Cancer Res. 2016 Sep;14(9):795-804
pubmed: 27353028
J Clin Oncol. 2016 Sep 20;34(27):3300-7
pubmed: 27480145
Mol Cancer Res. 2016 Dec;14(12):1195-1203
pubmed: 27604276
Ann Oncol. 2017 Mar 1;28(3):562-568
pubmed: 27993800
Cancer Discov. 2017 Jun;7(6):620-629
pubmed: 28242752
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28954285

Auteurs

Rebecca Carter (R)

NIHR University College London Hospitals Biomedical Research Centre, UCL Cancer Institute, University College London, London WC1E 6DD, UK.
NIHR Oxford Biomedical Research Centre, Department of Oncology, University of Oxford, Oxford OX1 2JD, UK.

Azadeh Cheraghchi-Bashi (A)

NIHR Oxford Biomedical Research Centre, Department of Oncology, University of Oxford, Oxford OX1 2JD, UK.

Adam Westhorpe (A)

NIHR University College London Hospitals Biomedical Research Centre, UCL Cancer Institute, University College London, London WC1E 6DD, UK.
NIHR Oxford Biomedical Research Centre, Department of Oncology, University of Oxford, Oxford OX1 2JD, UK.

Sheng Yu (S)

Computational Biology and Integrative Genomics, University of Oxford, Oxford OX1 2JD, UK.

Yasmin Shanneik (Y)

NIHR Oxford Biomedical Research Centre, Department of Oncology, University of Oxford, Oxford OX1 2JD, UK.

Elena Seraia (E)

NDM Research Building, Nuffield Department of Medicine, University of Oxford, Oxford OX1 2JD, UK.

Djamila Ouaret (D)

Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX1 2JD, UK.

Yasuhiro Inoue (Y)

Mie University, Graduate School of Medicine, Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Edobashi 2-174, Tsu, Japan.

Catherine Koch (C)

Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA.

Jenny Wilding (J)

Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX1 2JD, UK.

Daniel Ebner (D)

Target Discovery Institute, National Phenotypic Screening Centre, Nuffield Department of Medicine, University of Oxford, Oxford OX1 2JD, UK.

Anderson J Ryan (AJ)

CRUK & MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX1 2JD, UK.

Francesca M Buffa (FM)

CRUK & MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX1 2JD, UK.

Ricky A Sharma (RA)

NIHR University College London Hospitals Biomedical Research Centre, UCL Cancer Institute, University College London, London WC1E 6DD, UK.
NIHR Oxford Biomedical Research Centre, Department of Oncology, University of Oxford, Oxford OX1 2JD, UK.

Classifications MeSH